Becker M O
Klinik für Rheumatologie, Universitätsspital Zürich, Gloriastr. 25, 8091, Zürich, Schweiz.
Internist (Berl). 2016 Dec;57(12):1155-1163. doi: 10.1007/s00108-016-0148-1.
Systemic sclerosis (scleroderma) is a rheumatologic disease characterised not only by inflammation/autoimmunity, but also by tissue fibrosis and vascular lesions. The therapeutic approach to patients is dictated by the organ involvement and includes treatment of vascular and fibrotic disease features beyond mere immunosuppression. Fibrotic features in particular, are still inadequately treated, whereas many drugs have been tested for vascular complications within recent years. In this review, the currently available treatment options for this rare disease are presented. Therapy options in systemic sclerosis have changed over the past 10 years and this trend will also continue in the future.
系统性硬化症(硬皮病)是一种风湿性疾病,不仅以炎症/自身免疫为特征,还伴有组织纤维化和血管病变。对患者的治疗方法取决于器官受累情况,包括治疗血管和纤维化疾病特征,而不仅仅是免疫抑制。特别是纤维化特征仍未得到充分治疗,而近年来已经对许多药物进行了血管并发症方面的测试。在本综述中,介绍了针对这种罕见疾病目前可用的治疗选择。过去10年中系统性硬化症的治疗选择发生了变化,这种趋势在未来也将持续。